Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.68 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.68 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2627117 | 0.88 | SYK (0.71) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL22067873 | 0.88 | MAPK8 (0.64) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL4710859 | 0.83 | SYK (0.76) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL4710858 | 0.83 | SYK (0.76) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL16195068 | 0.83 | SYK (0.90) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL17191597 | 0.83 | SYK (0.90) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL14038888 | 0.83 | SYK (0.84) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL13624981 | 0.82 | SYK (0.80) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL4715151 | 0.81 | SYK (0.83) | SYKMAPK3MAPK1KCNH2AURKB | |
| SCHEMBL16195116 | 0.81 | SYK (1.00) | SYKMAPK3MAPK1KCNH2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181164-A1 | Thienopyranones and Furanopyranones as Checkpoint Inhibitors and Modulators of Anti-Tumor Immunity | SIGNALRX PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181164-A1 | Thienopyranones and Furanopyranones as Checkpoint Inhibitors and Modulators of Anti-Tumor Immunity | CDK6, BTK, CDK1 | SYK 17/4885MAPK3 357/4885MAPK1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.